drugset / Trial / NCT06042257
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
Phase 2
Terminated
3 enrolled
Rachel G. Greenberg, MD, MB, MHS
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collabThe Emmes Company, LLC · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children 6-12 years of age with Down syndrome (DS) after 8 weeks of treatment.
Timeline
- Start
- 2024-12-09
- Primary completion
- 2025-05-17
- Completion
- 2025-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Guanfacine | Small molecule | 0.5 mg | — |